GRAFORCE
15.5.2023 02:01:27 CEST | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Worley, a leading global engineering and project delivery business, are cooperating to scale methane electrolysis (plasmalysis) starting in Australia, Pacific, Asia and China. Plasmalysis is a game changing technology, which converts natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting CO2 or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or mode of transportation. Graforce and Worley will present plasmalysis plants at APPEA 2023 in Adelaide, Australia (15-18 May) at the Worley sponsored Hydrogen Pavilion showcasing latest innovations in the hydrogen industry and its impact on decarbonization of industries and fossil fuels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005004/en/
Methane Plasmalysis plants – graphics shows a 12 MW plant - convert natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting carbon dioxide or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or way of transportation. (Graphic: Business Wire)
Australia is among the largest producers of natural gas and one of the world's leading fuel suppliers. Projects to supply Germany with LNG and green hydrogen are in progress. At the same time, the country aims to reduce its CO2 emissions by more than 40 percent by 2030. Sustainable technologies like plasmalysis are an essential requirement to meet both, economic and climate targets.
“The entire APAC region is looking for green technologies for existing energy sources to achieve climate targets. The cooperation with Worley is an important step for us to quickly scale our methane plasmalysis and to open up these markets,” said Dr. Jens Hanke, CTO of Graforce.
Worley provides large scale engineering, procurement, and construction services to the energy, resources, and chemicals industries. Worley will provide engineering and project delivery services for plasmalysis plants customers in Australia and Asia. In the modular plants, a high-frequency plasma field generated by renewable electricity splits hydrocarbons such as methane into their molecular components: hydrogen and solid carbon. Compared to water electrolysis, plasmalysis requires only one-fifth the energy to produce the same amount of hydrogen. A single 20-megawatt plant can convert about 70,000 metric tons of methane into hydrogen per year and eliminate about 200,000 metric tons of CO2 emissions.
“As we scale up towards the vast quantities of renewable energy and hydrogen required to meet our Net Zero goals, our medium-term reliance on fossil fuels and in particular, natural gas and LNG, is a given. Plasmalysis marries these two realities together and enables faster decarbonisation utilising existing infrastructure. Plasmalysis is likely to be a valuable tool in the decarbonisation toolbox and contribute to our company purpose of delivering a more sustainable world,” says Gillian Cagney, Worley ANZ Managing Director.
About
Graforce is a German hydrogen technology company. Their power-to-X plants produce carbon dioxide free or carbon dioxide negative hydrogen and synthetic feedstocks – with highest efficiency and lower infrastructure costs in the multi-megawatt range. Thus, Graforce decarbonizes fossil energies, industries and the heat, transport and building sectors. Graforce is currently in the process of expanding its financial and strategic partnerships to quickly scale its hydrogen technology worldwide.
Worley is a global company headquartered in Australia and our purpose is delivering a more sustainable world. Worley is a leading global provider of professional project and asset services in the energy, chemicals and resources sectors. As a knowledge-based service provider, we use our knowledge and capabilities to support our customers to reduce their emissions and move towards a low carbon future. Worley Limited is listed on the Australian Securities Exchange (ASX: WOR).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom